Nebivolol Krka (Nebivolol)

Nebivolol is prescribed for cardiovascular conditions that benefit from β1‑adrenergic blockade and vasodilation.

• Hypertension: lowers both systolic and diastolic blood pressure, reducing cardiovascular risk and improving long‑term control in patients with elevated arterial pressure.
• Heart failure: enhances left‑ventricular ejection fraction and alleviates symptoms such as dyspnea and fatigue in adults with chronic heart failure, supporting better functional capacity.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility. Concurrently, it stimulates endothelial nitric oxide synthase, increasing nitric oxide release which causes peripheral vasodilation. The combined effect reduces systemic vascular resistance and arterial pressure while improving myocardial oxygen supply.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness or light‑headedness: related to blood pressure reduction.
• Fatigue: general tiredness, especially during dose titration.
• Bradycardia: slower than normal heart rate.
• Nausea: occasional stomach upset.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Hypotension: dangerously low blood pressure causing fainting.
• Bronchospasm: airway constriction, particularly in patients with asthma.
• Heart block: impaired electrical conduction of the heart.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Liver enzyme elevation: abnormal liver function tests.

Before initiating Nebivolol, consider the following safety measures.

• Cardiovascular assessment: evaluate heart rate, blood pressure, and cardiac function.
• Concomitant beta‑blockers: avoid combining with other β‑blockers to prevent excessive blockade.
• Asthma or COPD: use with caution as β2‑receptor effects may exacerbate bronchospasm.
• Diabetes: monitor blood glucose as beta‑blockade can mask hypoglycaemia symptoms.
• Pregnancy and lactation: discuss potential risks with a healthcare professional before use.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Other beta‑blockers: additive cardiac depression and bradycardia.
• Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block and severe hypotension.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Antihypertensives (ACE inhibitors, ARBs, diuretics): monitor for excessive blood pressure drop.

• NSAIDs: may blunt antihypertensive effect.
• Antiarrhythmics (amiodarone, sotalol): watch for conduction abnormalities.
• Antidiabetic agents: observe for masked hypoglycaemia signs.